Login to Your Account

NeurogesX Reports Positive Phase III Study Of NGX-4010

By Jim Shrine

Wednesday, September 5, 2007
NeurogesX Inc. reported the pain patch NGX-4010 met primary and secondary endpoints in a third Phase III trial, and the second in patients with postherpetic neuralgia. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription